NTLA-2001

AssetAlso called nexiguran ziclumeran

CRISPR-mediated disruption of hepatic TTR reduces transthyretin production and subsequent amyloid deposition.

Stage
Phase 3
Modality
Gene editing
Target
TTR
12
Indications
3
Trials
1
Developer

2 trials are still running. Trial NCT06672237 updated in its registry on Nov 5, 2026. clinicaltrials.gov

Indications

12

9 more

In the full profile

  • Target and mechanism1
  • Owner and partners2
  • Trials3
  • Evidence for its targets2
  • Competitors8
  • Aging relevance1
  • Signals3

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets